source
- Bristol Myers reports 52% reduction in progression risk for next-gen multiple myeloma drug in Phase 3 trialBristol Myers Squibb said its next-generation multiple myeloma therapy, positioned as a successor to Pomalyst, lowered the risk of disease progression or death by 52% when added to a standard combi…
- Pfizer partners with China's Innovent Biologics on $10 billion cancer drug collaborationPfizer announced a major partnership with Chinese biotech Innovent Biologics, valued at over $10 billion, to develop cancer therapies. The agreement covers up to 12 antibody-based candidates, incl…